1stOncology™: Cancer Intelligence Service – Page 6053 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

QSAM Biosciences Announces Reverse Stock Split Effective March 10, 2022

On March 9, 2022 QSAM Biosciences, Inc. (the "Company") (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of cancer and related diseases, reported that a 1-for-40 reverse stock split of the Company’s common stock will become effective on Thursday, March 10, 2022 (Press release, QSAM Biosciences, MAR 9, 2022, View Source [SID1234609777]). The reverse stock split was approved by the Company’s Board of Directors in connection with the Company’s application to list its common shares on The NASDAQ Capital Market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Pursuant to the reverse stock split, each forty (40) shares of the Company’s outstanding common stock, $0.0001 par value per share, will be automatically combined and converted into one (1) outstanding share of common stock, $0.0001 par value per share. As a result of this reverse stock split, the Company’s outstanding common shares will be reduced to approximately 1,686,321 shares, exclusive of convertible preferred shares and convertible notes representing approximately an additional 450,000 issuable common shares.

Shares of the Company’s common stock will be assigned a new CUSIP number (74738N202) and are expected to begin trading on a split-adjusted bases, beginning on Thursday, March 10, 2022. As part of the reverse stock split, a "D" will be placed on the ticker symbol for 20 business days. After 20 business days or until listing on the Nasdaq Capital Market, the symbol will then change back to QSAM.

No fractional shares will be issued and any fractional shares resulting from the reverse stock split will be rounded up to the next whole share. Stockholders holding shares of QSAM common stock at registered brokerage firms, should consult with their broker for further information on their account. Stockholders who hold shares with our transfer agent will receive information in the mail about their accounts over the next few days.

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

On March 9, 2022 Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, reported that company leadership is scheduled to participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference, on Wednesday, March 16, 2022, at 10:40 a.m. ET (Press release, Viracta Therapeutics, MAR 9, 2022, View Source [SID1234609776]).

A webcast of the fireside chat will be available on the Investors section of the Viracta website under "Events and Webcasts" at View Source The webcast will be archived for 30 days.

Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement

On March 9, 2022 Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, reported that it has closed its previously announced private placement with a leading healthcare investor (Press release, Brooklyn ImmunoTherapeutics, MAR 9, 2022, View Source [SID1234609775]). The gross proceeds to Brooklyn from the private placement, before deducting the placement agent’s fees and other estimated fees and expenses related to the offering payable by Brooklyn, were approximately $12 million. Brooklyn intends to use the net proceeds from the private placement for general working capital purposes.

Pursuant to the terms of the securities purchase agreement, Brooklyn issued 6,857,142 units at a price of $1.75 per unit to the investor. Each unit consisted of one share of common stock (or one pre-funded warrant in lieu thereof), and a five-and-a-half-year warrant to purchase one share of common stock at an exercise price of $1.91 per share.

Cantor Fitzgerald & Co. acted as placement agent for the private placement.

The securities were offered and sold in a private placement and were not registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Brooklyn has agreed to file a resale registration statement with the Securities and Exchange Commission (the "SEC"), for purposes of registering the resale of the shares of common stock issued or issuable in connection with the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Corporate Presentation dated March 2022

On March 9, 2022, Keros Therapeutics, Inc. (the "Company") Presented its corporate presentation (Presentation, Keros Therapeutics, MAR 9, 2022, View Source [SID1234609774]).

Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference

On March 9, 2022 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that it will webcast its presentation at the 32nd Annual Oppenheimer Healthcare Conference at 6:20 a.m. PT on Wednesday, March 16, 2022 (Press release, Sana Biotechnology, MAR 9, 2022, View Source [SID1234609773]). The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

The webcast will be accessible on the Investor Relations page of Sana’s website at View Source A replay of the presentation will be available at the same location for 30 days following the conference.